Latest news with #www.iotamotion.com
Yahoo
2 days ago
- Business
- Yahoo
iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology
ST. PAUL, Minn., June 11, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, today announced the issuance of U.S. Patent No. 12,311,173. This new patent strengthens iotaMotion's intellectual property portfolio and supports the company's mission to advance cochlear implant surgery beyond human capability. The patent covers concepts including systems for utilizing separate positioning and power components to streamline the intraoperative use of robotically controlled positioning. "This patent represents a significant milestone for iotaMotion as we continue to build out our IP portfolio and expand our technology roadmap," said Mike Lobinsky, CEO & President of iotaMotion. The announcement comes on the heels of recent NIH grant awards leveraging the core technology platform of the iotaSOFT® Insertion System: Phase I grant awarded to Qualia Oto to evaluate potential applications for robotic assistance to assist in array insertion using novel shape-changing polymers Phase I grant awarded to iotaMotion to support the development of a navigation-based cochlear implant insertion to optimize trajectory during insertion "We are proud to see our industry-leading efforts recognized through this patent. Alongside recent grant-funded initiatives, this milestone reinforces the role our technology plays in both clinical practice and advancing research to shape the future of cochlear implantation," said Costa Nikou, Chief Technology Officer at iotaMotion. iotaMotion continues to advance the field of cochlear implantation through partnerships with academic and industry collaborators. Looking ahead, cochlear implantation is expected to integrate robotic assistance with enabling technology such as navigation and electrocochleography. With hundreds of successful insertions with the iotaSOFT Insertion System completed at more than 25 centers across the United States, iotaMotion will continue to expand commercially, while innovating on its product roadmap. About iotaMotion iotaMotion, Inc. is a medical technology company based in St. Paul, MN, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT® Insertion System, is designed to provide a slow and consistent electrode array insertion that is designed to preserve delicate intracochlear structures. The system is commercially available in the United States and under clinical investigation in other global markets. For more information, visit or contact Wade Colburn, Vice President of Marketing and Clinical, at pr@ View original content to download multimedia: SOURCE iotaMotion, Inc.
Yahoo
13-05-2025
- Business
- Yahoo
iotaMotion Announces First Use of Robotic-Assisted Cochlear Implant Technology Outside the U.S. as Part of Clinical Investigation in Switzerland
ST. PAUL, Minn., May 14, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is in use as a pre-market clinical investigation at University Hospital of Zurich, led by Professor Alexander Huber. The study, titled "Analysis of electrocochleographic signals during speed-controlled cochlear implant electrode array insertion in a non-randomized controlled trial," represents a significant milestone in iotaMotion's history and the broader cochlear implant market. The iotaSOFT Insertion System, which has been used in more than 750 cases in the United States, provides unprecedented control of the electrode array insertion, enabling the optimization of intracochlear recordings using real-time electrocochleography (ECochG). Professor Huber highlighted the significance of the collaboration: "Bringing this new robotic-assisted technology for cochlear implantation to University of Zurich was extremely important to our team. It will enable us to continue to advance cochlear implant care and explore techniques that have never been used clinically prior to this study." The study leverages robotic control of the array insertion to analyze the relationship between electrode insertion dynamics and cochlear function, as measured by ECochG signals. This approach may pave the way for future advancements in cochlear implant programming and hearing preservation strategies. "This represents a major milestone for iotaMotion as we expand outside of the United States with our technology," said Mike Lobinsky, President & CEO of iotaMotion. "The team in Zurich has been an exceptional partner, and we look forward to continuing our relationship." While currently under pre-market clinical investigation, wider availability of the iotaSOFT Insertion System is planned for 2026. About iotaMotion iotaMotion, Inc. is a medical technology company based in St. Paul, MN, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT® Insertion System, is designed to provide a slow and consistent electrode array insertion that is designed to preserve delicate intracochlear structures. The system is commercially available in the United States and under clinical investigation in other global markets. For more information, visit or contact Wade Colburn, Vice President of Marketing and Clinical, at pr@ Logo - View original content: SOURCE iotaMotion, Inc. Sign in to access your portfolio
Yahoo
13-05-2025
- Business
- Yahoo
iotaMotion Announces First Use of Robotic-Assisted Cochlear Implant Technology Outside the U.S. as Part of Clinical Investigation in Switzerland
ST. PAUL, Minn., May 14, 2025 /PRNewswire/ -- iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, today announced the first use of the iotaSOFT® Insertion System outside of the United States. The technology is in use as a pre-market clinical investigation at University Hospital of Zurich, led by Professor Alexander Huber. The study, titled "Analysis of electrocochleographic signals during speed-controlled cochlear implant electrode array insertion in a non-randomized controlled trial," represents a significant milestone in iotaMotion's history and the broader cochlear implant market. The iotaSOFT Insertion System, which has been used in more than 750 cases in the United States, provides unprecedented control of the electrode array insertion, enabling the optimization of intracochlear recordings using real-time electrocochleography (ECochG). Professor Huber highlighted the significance of the collaboration: "Bringing this new robotic-assisted technology for cochlear implantation to University of Zurich was extremely important to our team. It will enable us to continue to advance cochlear implant care and explore techniques that have never been used clinically prior to this study." The study leverages robotic control of the array insertion to analyze the relationship between electrode insertion dynamics and cochlear function, as measured by ECochG signals. This approach may pave the way for future advancements in cochlear implant programming and hearing preservation strategies. "This represents a major milestone for iotaMotion as we expand outside of the United States with our technology," said Mike Lobinsky, President & CEO of iotaMotion. "The team in Zurich has been an exceptional partner, and we look forward to continuing our relationship." While currently under pre-market clinical investigation, wider availability of the iotaSOFT Insertion System is planned for 2026. About iotaMotion iotaMotion, Inc. is a medical technology company based in St. Paul, MN, dedicated to advancing cochlear implant surgery beyond human capability through robotic-assisted solutions. Its flagship technology, the iotaSOFT® Insertion System, is designed to provide a slow and consistent electrode array insertion that is designed to preserve delicate intracochlear structures. The system is commercially available in the United States and under clinical investigation in other global markets. For more information, visit or contact Wade Colburn, Vice President of Marketing and Clinical, at pr@ Logo - View original content: SOURCE iotaMotion, Inc. Sign in to access your portfolio
